Management Team
Sudhir Agrawal, D. Phil. ׀ Chief Executive Officer and Chief Scientific Officer
Lou Arcudi ׀ Chief Financial Officer, Treasurer and Secretary
Alice S. Bexon, MBChB. ׀ Vice President, Clinical Development
Timothy M. Sullivan, Ph.D. ׀ Vice President, Development Programs
Ekambar R. Kandimalla, Ph.D. ׀ Vice President, Discovery
Steven J. Ritter, Ph.D., J.D. ׀ Vice President, Intellectual Property and Contracts
David M. Lough, Ph.D. ׀ Director, Business Development and Alliance Management
Frank Whalen, C.P.A. ׀ Controller
Sudhir Agrawal, D. Phil. ׀ Chief Executive Officer and Chief Scientific Officer
Since joining the Company in 1990, Dr. Agrawal has served in various capacities including Vice President of Discovery, Senior Vice President of Discovery, and Acting Chief Executive Officer. He was appointed Chief Scientific Officer in January 1993, President in February 2000, and Chief Executive Officer in August 2004. Dr. Agrawal has led the Company’s transition into the discovery and development of targeted immune therapy based on Toll-like receptors.
Dr. Agrawal received his D. Phil. in Chemistry in 1980 and carried out his post-doctoral research at the Medical Research Council's Laboratory of Molecular Biology in Cambridge, U.K. While working at Worcester Foundation of Experimental Biology, he carried out work in antisense technology with Paul Zamecnik, MD, and based on this technology, the Company was founded.
Dr. Agrawal has published over 275 research papers/reviews and has edited two volumes on oligonucleotide chemistry and one on antisense therapeutics. He has also authored over 300 patents, issued or pending worldwide. He is a member of the editorial board of Oligonucleotides, Trends in Molecular Medicine, IDrugs, and Human Vaccines.